Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

79 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
van Bodegraven AA, Bravenboer N, Witte BI, Dijkstra G, van der Woude CJ, Stokkers PC, Russel MG, Oldenburg B, Pierik M, Roos JC, van Hogezand RA, Dik VK, Oostlander AE, Netelenbos JC, van de Langerijt L, Hommes DW, Lips P; Dutch Initiative on Crohn and Colitis (ICC). van Bodegraven AA, et al. Among authors: van der Woude CJ, van Hogezand RA, van de Langerijt L. Gut. 2014 Sep;63(9):1424-30. doi: 10.1136/gutjnl-2013-305523. Epub 2013 Oct 21. Gut. 2014. PMID: 24146170 Clinical Trial.
Is perianal Crohn's disease associated with intestinal fistulization?
Sachar DB, Bodian CA, Goldstein ES, Present DH, Bayless TM, Picco M, van Hogezand RA, Annese V, Schneider J, Korelitz BI, Cosnes J; Task Force on Clinical Phenotyping of the IOIBD. Sachar DB, et al. Among authors: van Hogezand RA. Am J Gastroenterol. 2005 Jul;100(7):1547-9. doi: 10.1111/j.1572-0241.2005.40980.x. Am J Gastroenterol. 2005. PMID: 15984979
Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease.
Meijer MJ, Mieremet-Ooms MA, van Hogezand RA, Lamers CB, Hommes DW, Verspaget HW. Meijer MJ, et al. Among authors: van Hogezand RA. World J Gastroenterol. 2007 Jun 7;13(21):2960-6. doi: 10.3748/wjg.v13.i21.2960. World J Gastroenterol. 2007. PMID: 17589947 Free PMC article.
Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease.
Gao Q, Meijer MJ, Schlüter UG, van Hogezand RA, van der Zon JM, van den Berg M, van Duijn W, Lamers CB, Verspaget HW. Gao Q, et al. Among authors: van Hogezand RA, van der Zon JM, van den Berg M, van Duijn W. Inflamm Bowel Dis. 2007 Jun;13(6):693-702. doi: 10.1002/ibd.20100. Inflamm Bowel Dis. 2007. PMID: 17243139 Clinical Trial.
Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.
D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P. D'haens G, et al. Among authors: Van Deventer S, Van Hogezand R. Gastroenterology. 1999 May;116(5):1029-34. doi: 10.1016/s0016-5085(99)70005-3. Gastroenterology. 1999. PMID: 10220494 Clinical Trial.
Effects of anti-tumour necrosis factor-alpha therapy on the quality of life in Crohn's disease.
van Balkom BP, Schoon EJ, Stockbrügger RW, Wolters FL, van Hogezand RA, van Deventer SJ, Oldenburg B, van Dullemen HM, Russel MG. van Balkom BP, et al. Among authors: van Hogezand RA, van Deventer SJ, van Dullemen HM. Aliment Pharmacol Ther. 2002 Jun;16(6):1101-7. doi: 10.1046/j.1365-2036.2002.01268.x. Aliment Pharmacol Ther. 2002. PMID: 12030951 Clinical Trial.
79 results
Jump to page
Feedback